At a Glance
- Company: BioArctic and Eli Lilly
- Location: Stockholm, Sweden
- Deal value: $30 million upfront, up to $770 million in milestones, plus royalties
- Focus area: Neurodegeneration and brain drug delivery
- Next steps: BioArctic will build a new drug candidate; Lilly will lead development and commercialisation
What happened?
BioArctic has signed a research and collaboration agreement with Eli Lilly to combine its BrainTransporter technology with an undisclosed Lilly drug candidate for neurodegeneration. The Swedish company said it will receive $30 million upfront and could earn up to $770 million more in milestone payments.
Why does it matter?
The deal targets one of neuroscience’s biggest obstacles: getting medicines across the blood-brain barrier. If successful, BrainTransporter could improve brain exposure, which may help with efficacy, safety and dosing convenience.
Who’s behind it?
BioArctic is a Stockholm-based biotech known for work in neurodegeneration and brain delivery technologies. Lilly is the pharmaceutical partner bringing the drug candidate and taking responsibility for global development and commercialisation.
How was it achieved?
Under the agreement, BioArctic will generate a new drug candidate by pairing BrainTransporter with a Lilly molecule. The platform uses transferrin receptor-mediated transport to help move therapies into the brain.
What’s next?
Lilly will handle worldwide development and future commercial activities if the programme advances. BioArctic said this is its fourth BrainTransporter partnership, suggesting the platform is becoming a broader partnering asset.